Significance of podoplanin expression in keratocystic odontogenic tumor

Journal of Oral Pathology and Medicine

Volumn 39, Issue 1, 2010, Pages 110-114

  Okamoto, Eri ^b,c   Kikuchi, Kentaro ^a,b   Miyazaki, Yuji ^b   González Alva, Patricia ^b   Oku, Yuka ^c   Tanaka, Akio ^c   Yoshida, Noriaki ^b   Fujinami, Masahiro ^b   Ide, Fumio ^b   Sakashita, Hideaki ^c   Kusama, Kaoru ^b  

^a Division of Pathology ^*  (Japan)

^b Department of Diagnostic and Therapeutic Sciences   (Japan)

^c MEIKAI UNIVERSITY SCHOOL OF DENTISTRY   (Japan)

Author keywords

Immunohistochemistry; Keratocystic odontogenic tumor; Orthokeratinized odontogenic cyst; Podoplanin

Indexed keywords

PODOPLANIN;

ARTICLE; CANCER INVASION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATOCYSTIC ODONTOGENIC TUMOR; MAJOR CLINICAL STUDY; ODONTOGENIC TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR CLASSIFICATION;

EID: 76249113665     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00851.x     Document Type: Article

References (21)

1. Philipsen HP. Keratocystic odontogenic tumor. In : Barnes L, Eveson JW, Reichart PA, Sidransky D, eds. WHO classification of tumours. Pathology and genetics. Head and neck tumors. Lyon : IARC Press, 2005 306 307.
2. Philipsen HP. Om keratocystedr (Kolesteratomer) and kaeberne. Tandlaegebladet 1956 60 : 963 971.
3. Sciubba JJ, Fantasia JE, Kahn LB. Tumors and cyst of the jaws. Washington, DC : Armed Force Institute of Pathology, 2001 34 40.
4. Schacht V, Ramirez MI, Hong YK, et al. T1α/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003 22 : 3546 3556.
5. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005 166 : 913 921.
6. Martín-Villar E, Megías D, Castel S, Yurrita MM, Vilaró S, Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 2006 119 : 4541 4553.
7. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006 9 : 261 272.
8. Wicki A, Christofori G. The potential role of podoplanin in tumor invasion. Br J Cancer 2007 96 : 1 5.
9. Wetterwald A, Hoffstetter W, Cecchini MG, et al. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 1996 18 : 125 132.
10. Petrova TV, Mäkinen T, Mäkelä TP, et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 2002 21 : 4593 4599.
11. Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 2003 162 : 575 586.
12. Dumoff KL, Chu CS, Harris EE, et al. Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Mod Pathol 2006 19 : 708 716.
13. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol 2005 26 : 195 200.
14. Martín-Villar E, Scholl FG, Gamallo C, et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005 113 : 899 910.
15. Yuan P, Temam S, El-Naggar A, et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006 107 : 563 569.
16. Nakayama Y, Matsumoto K, Nagato M, et al. Significance of lymphangiogenesis as assessed by immunohistochemistry for podoplanin in patients with esophageal carcinoma. Anticancer Res 2007 27 : 619 625.
17. Kono T, Shimoda M, Takahashi M, et al. Immunohistochemical detection of the lymphatic marker podoplanin in diverse types of human cancer cells using a novel antibody. Int J Oncol 2007 31 : 501 508.
18. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008 26 : 354 360.
19. Oku Y, Tanaka A, González-Alva P, Sakashita H, Kusama K. Podoplanin expression in human pleomorphic adenomas. In : Varma AK, Qiu WL, Zhang CP, Zhang ZY, eds. Oral oncology. Vol 12. Shanghai, China : Ocean Papers & Printers, 2008 12 : 251 253.
20. González-Alva P, Tanaka A, Oku Y, et al. Enhanced expression of podoplanin in ameloblastoma. J Oral Pathol Med 2009 (In press).
21. Miyazaki Y, Okamoto E, González-Alva P, et al. The significance of podoplanin expression in human inflamed gingival. J Oral Sci 2009 51 : 283 287.